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Abstract 
 
Mammalian cells possess multiple sensors for recognition of broad 
range of microbes. This recognition occurs through specific molecular 
signatures found across various pathogens. Toll-like receptors (TLRs), 
RIG-I-like receptors (RLRs), NOD-like receptors (NLRs) and C-type 
lectin receptors (CLRs) are the major cellular PRRs responsible for 
this recognition. TLRs are transmembrane sensors, whereas other 
PRRs mainly localize in the cytoplasm for the activation of type I IFNs 
and pro-inflammatory cytokines. Among these PRRs, RLRs are well 
known for its indispensable role in sensing the invasion of RNA 
viruses. This review summarizes recent advances in viral recognition 
by RLRs and their signalling pathways, and introduces newly 






Interferon system is well known for its essential role in mounting the first 
line defence against infectious pathogens for the past decades. This system 
can be divided into two types—type I and type II. Type I interferons 
comprised of several members; one of the example would be interferon 
α/β superfamily, while type II interferon only consists of interferon-γ. 
These cytokines were firstly identified as the key proteins to suppress viral 
replication. They are produced by viral infected cells through the initiation 
of the first round of signalling cascade, activating several major 
transcription factors such as ATF/c-jun, IRFs and NF-κB family members, 
and eventually lead to the production of mature interferon proteins. These 
proteins will be secreted to the circulation system and bound interferon 
receptors on the cell surface, which in turn triggered a series of 
dimerization and phosphorylation derived modifications, initiating the 
secondary signalling cascade known as JAK-STATs pathways, activating 
the transcription of numerous interferon-stimulated genes (ISGs).  
Investigation of the underlying biochemical mechanisms responsible for 
interferon production, from transmitting signals after pathogens infections 
to the activation of transcription factors that drives interferon expression 
within the nucleus, has been a major focus in this field. It was believed 
that within cells there exist sensors or receptors that can recognize distinct 
molecular structure that are broadly shared by pathogens (1). In the past 
few decades, numerous efforts have been invested to identify these 
pathogen-recognition receptors (PRRs). To date, major PRRs that have 
been successfully identified include Toll-like receptors (TLRs), retinoic 
acid-inducible gene-I (RIG-I)-like receptors (RLRs), NOD-like receptors 
(NLRs) and C-type lectin receptors (CLRs). NLRs are mainly responsible 
for intracellular inflammatory responses, while CLRs are mainly 
responsible for sensing the C-type lectin-like domain that is mainly found 
in fungi and bacterial (2,3). RLRs mainly functions as cytoplasmic sensors 
for broad range of viruses, whereas well characterized TLRs are known to 
detect broad range of pathogens.  
Recent studies have also provided us important insights about the 
mechanism whereby these PRRs regulate both innate and adaptive 
immune responses in distinct type of cells; for example, TLR-mediated 
control of immune responses is mainly orchestrated by immunological 
cells such as macrophages and dendritic cells (DCs). Despite their 
dispensable role in plasmacytoid DCs (pDCs), RLRs are still the core 
molecule responsible for activation of both pro-inflammatory cytokine 
genes and cytokine-stimulated genes in a broad range of cells, including 
myeloid DCs (mDCs; also known as conventional DCs), coordinating the 
first-line of host systemic defences.  
In the following article, we will discuss recent advances in our knowledge 
of the underlying molecular mechanisms whereby the interferon system 
and other cytokines are stimulated by RLRs. In parallel, some comparisons 
with TLRs will be depicted through illustrations and tables. Detail 
advances in TLRs and other PRRs such as NLRs have been reviewed 




The family of RIG-I-like receptors 
 
The discovery of RLRs 
In the year 2004, RIG-I was identified by Yoneyama, M et al. (6) as a 
novel cytoplasmic viral sensor through a series of complementary DNA 
libraries screening in polyI:C stimulated cells (polyI:C is a variable length 
synthetic analogue of double-stranded RNA). Colonies showing 
significantly enhanced responses towards an IRF3-based reporter 
(p55C1B-Luc) were selected for sequencing and ‘blasted’ for potential 
candidates. Among the 1x10
5
 clones, RIG-I was identified (6). Gene-
targeting of the endogenous RIG-I in mouse-embryonic fibroblasts 
severely abrogated type I IFN production and ISG activation and, hence, 
potentiate viral replication. These extensive studies, combined with 
numerous biochemical analyses indicated that RIG-I plays a key role in 
mounting the first line defence against RNA viral invasion and, in part, 
against DNA viruses within cytoplasm through eliciting type I IFN 
production.  
 
RIG-I (which is encoded by the DDX58 gene) and its closely related RLR-
family members—melanoma differentiation associated factor 5 (MDA5; 
encoded by the IFIH1 gene) and laboratory of genetics and physiology 2 
(LGP2; encoded by the DHX58 gene)—belong to the family of DExD/H 
(Asp-Glu-x-Asp/His) box RNA helicases. Such helicases move along the 
nucleic-acid phosphodiester backbone, altering the secondary structure and 
using ATP for energy. All three RLR-family members contain a central 
helicase domain with ATPase catalytic activity, which is essential for viral 
double-stranded RNA (dsRNA) binding (6); and a repressing domain (RD) 
in the C-terminal domain (CTD), which is essential for autoregulation and 
binding with the 5’-triphosphate end of the viral genome (6,7). Despite 
sharing these similarities, they do have some differences (Figure 1): both 
RIG-I and MDA5 possess two tandem CARD domains at the N-terminal 
region, which is responsible for downstream signal transduction and 
activation of type I IFN genes after the recognition of non-self RNA (6); 
on the other hand, LGP2 lacks this signalling domain, suggesting that 
LGP2 is more likely to be a regulatory molecule rather than functioning as 
a signal inducer. 
RLR-mediated sensing of viruses and the specificity of viral PAMPs  
 
RLRs are known to confer recognition of various types of RNA and DNA 
viruses. Substantial progress has been made in defining the specific RNA 
signatures recognised by each RLR. In RIG-I-deficient fibroblast cells, 
little cytokine is produced in response to Paramyxoviruses such as 
Newcastle disease virus (NDV) and Sendai virus (SeV), rhabdoviruses 
such as vesicular stomatitis virus (VSV) (8,9), flaviviruses such as 
hepatitis C virus (HCV) and Japanese encephalomyocarditis virus (JEV) 
(10,11), and orthomyxoviruses such as influenza A and B (12,13). In 
contrast MDA5, despite being closely related to RIG-I, mainly recognizes 
Picornaviruses such as encephalomyocarditis virus (EMCV), poliovirus, 
Theiler’s murine encephalomyelitis virus (TMEV) and Mengo viruses (11). 
In addition, west Nile virus (WNV) and dengue virus are recognized by 
both receptors. In the case of chemically defined oligonucleotides, RIG-I 
mainly recognizes double-stranded blunt-ended dsRNA and single-
stranded RNA bearing 5’-triphosphate. Removing all three phosphates 
groups through phosphatase treatment, or using chemically synthesized di- 
or mono-phosphate ssRNA does not activate RIG-I-dependent signalling. 
Based on previous studies, RIG-I could also triggered IFN-gene activation 
in response to RNA products reverse-transcribed from the genome of 
DNA viruses through cytoplasmic RNA polymerase III (14,15). By using 
chemically synthesized polydA:dT, these studies proposed this novel role 
of RIG-I as an ‘indirect’ DNA sensor. In addition, the ‘panhandle’ 
structure found in the influenza genome, RNAs cleaved by RNase-L (an 
interferon-induced ribonulease) and polyU/UC-rich RNA (e.g. the 3’UTR 
of HCV) were also reported to be ligands for RIG-I (13, 16-17). Strikingly, 
Luthra et al. (18) provide evidence that viral mRNA from parainfluenza 5 
viruses could activate IFN production through an MDA5–RNase-L 
pathway. Unlike previous observations that used chemically synthesized 
oligonucleotides, this is the first evidence reporting a bona fide single-
stranded ligand that could activate MDA5; moreover, it’s a viral mRNA 






Since RNase-L is essential for the activation of IFN production by 
MDA5–RNase-L, the catalytic processing activity of RNase-L is 
inevitably involved, and some modifications as a result of cleavage by 
RNase-L might contribute. Since the exact RNA signature was not well 
characterized in this study, further analysis in this direction might revealed 
a brand new activation mode of MDA5. Long, synthetic dsRNAs such as 
polyI:C are known to be MDA5 ligands, whereas short polyI:C molecules 
turn out to be ligands for RIG-I (19). Other potential ligands for RLRs are 
summarized in Table 1. Substantial progress in structural analysis further 
confirmed these predictions (20-23). Collectively, the length and the 
composition and/or defined secondary structures of RNA might determine 





Structural analysis of RIG-I 
 
Numerous questions regarding the activation mode of RIG-I remain 
unsolved, particularly how each domain contributes to the conformational 
change of RIG-I upon engagement with viral RNA. Efforts in deciphering 
the structure of RIG-I have been tremendous. Here, we will discuss some 
of the newly proposed structural models of RIG-I activation. 
Previously, it has been proposed that the basic structural mode of RIG-I 
remains in a ‘closed’ conformation and undergoes conformational changes 
after binding to its RNA ligand, exposing the CARD domains for 
signalling and eventually alerting the cell about viral invasion (23) (Figure 
2A). 
In the same issue of Cell in 2011, Luo et al. (24) and Kowalinski et al. (25) 
independently revealed some new structural insights into RIG-I activation. 
In these reports, both groups concomitantly resolved the structure of 
several key RIG-I domains-Helicase-1 (Hel1; from human RIG-I [hRIG-I] 
aa236–455 and duck RIG-I [dRIG-I] aa242–456) and Helicase-2 (Hel2; 
from hRIG-I aa456–795 and duck RIG-I aa458–794). 
 
Hel2 further includes two subdomains, known as Hel2 insertion domain 
(Hel2i) and the ‘pincher/bridging’ domain. Through crystallization of 
human truncated RIG-I mutants, Luo et al. (24) showed that the RNA 
binding activity of RIG-I is regulated through multiple domains in an 
orchestrated way. For example, they showed that Hel2i specifically detects 
dsRNA, whereas the pincher/bridge domain possesses a V-shaped 
structure and mainly functions in controlling both Hel1–Hel2 and the CTD 
upon binding with RNAs, pinching them into a central groove with a 
‘closed clamping’ structure. This model suggests that the pincher/bridge 
domain could act as the ‘messenger’ to communicate between the CTD 
and Helicase domains. 
In addition, Luo et al. (24) demonstrated that the oligomerization of RIG-I 
is dependent on RNA length, with a minimal length of 18bp of dsRNA 
being necessary to significantly induce the oligomerization of RIG-I, and 
that ATPase activity is dispensable for this aspect. In their experiment, the 
maximum length of dsRNA used was only a 22-mer, unlike previously 
published work carried out in vivo, in which dsRNA with a length up to 1 
kbp could still activate RIG-I (19). Solving the structural changes of RIG-I 
using RNAs with different lengths and sequence composition might be 
interesting. 
In conclusion, Luo et al. (24) successfully highlighted the functional 
importance of several previously undefined subdomains in coordinating 
the conformational changes of RIG-I. Their experimental observations are 
still, however, insufficient to define the exact sequential changes in RIG-I 
architecture from RNA sensing to signalling, as crystallization of full-
length human RIG-I poses a daunting challenge. 
In the same issue of Cell, Kowalinski et al. (25) made a remarkable step in 
answering this question of how RIG-I transmit sensing to signalling. By 
using intense X-ray beams, the authors further verified that in the 
quiescent state, instead of the ‘closed’ conformation as previously 
anticipated, RIG-I possesses a ‘partially open’ conformation. The CARDs 
are sequestered together with Hel2i, with a linker sterically hindering the 
binding of viral RNA to the helicase and hindering the ubiquitination of 
CARD by tripartite-motif-containing 25 (TRIM25). In biochemical 
pulldown assays, purified dRIG-I CARD is able to bind to Hel2i. These 
findings further rationalized our understanding that the CTD domain is not 
essential for the autorepressing function but the CARD domains are 
crucial in maintaining RIG-I in a non-active state. In contrast, the CTD 
region is flexibly exposed, with no strong chemical interactions with the 
other domains, and can thus fulfill a sensing role (25). 
On the basis of these observations, Kowalinski et al. (25) proposed 
a sequential RIG-I activation model — upon binding with viral 5’- 
triphosphate dsRNA by the CTD, signals triggered the pinching of both 
the helicase domains and the CTD–dsRNA complex by the V-shaped 
pincher/bridging domain; the helicase domain is flexibly adapted to fit in 
the viral dsRNA after ATP hydrolysis. This cooperative binding results in 
a strong and stable V-groove closed-clamping complex, and eventually 
promotes the expulsion of the CARD regions, leaving them exposed for 
interaction with MAVS (Figure 2B). Despite their novelty, it should be 
noted that these observations were conducted using dRIG-I, with only 
53% homology to hRIG-I. The hRIG-I activation mechanism might differ; 
thus complementary studies comparing the human equivalent are 
definitely required. In general, these reports further advanced our 
understanding of the molecular architecture of RIG-I during signal 
activation. 
 
The RLRs-mediated signalling 
Events that follow RLR recognition of viral PAMPs 
Upon virus infection, RIG-I recognizes dsRNA with 5`-triphosphate as the 
PAMP, being distinct from self-RNA. In the quiescent state, both RIG-I 
and MDA5 remain in a partially closed conformation; after binding with 
its molecular PAMPs, RIG-I undergoes conformational changes by 
exposing its CARD-domain and forming a translocon complex with a 
chaperone molecule called 14-3-3ε (26). This chaperone mainly functions 
as a scaffold for stabilizing TRIM25-mediated ubiquitination and 
facilitates the translocation of RIG-I–ligand complexes to mitochondria to 
form homotypic interactions with the CARD region of its adapter, MAVS, 
which is predominantly located on mitochondria, for downstream signal 
transduction (27). This interaction further induces the assembly of 
numerous proteins to form complexes; examples of these proteins are 
STING (stimulator of IFN genes; also known as MITA [mediator of IRF3 
activation], ERIS [endoplasmic reticulum interferon stimulator] or MYPS 
[a motif from DNA polymerase]), TRADD, FADD, RIP1, caspases and 
TRAF2/3/6 (28-35). These complexes further induce the activation of both 
NF-κB and IRF3 through IKKα–IKKβ and TBK1–IKKγ complexes, 
respectively, and eventually trigger the transcription of type I IFN genes 
and other pro-inflammatory cytokines (Figure 3). 
The role of LGP2 
LGP2, a member of the RLR family, has been proposed to have a 
regulatory function for both RIG-I and MDA5. In vivo studies using 
LGP2-deficient cells revealed that cytokine production was impaired after 
viral infection (36,37), whereas in vitro overexpression of LGP2 inhibits 
IFN-β production (9). Since LGP2 lacks a CARD domain, major 
functional analyses, such as the RNA binding activities and ATPase 
activity, mainly focus on its CTD and helicase domains. Biochemical and 
structural analyses demonstrate that the CTD of LGP2 could bind to both 
ssRNA and dsRNA with higher affinity than RIG-I and MDA5 do (38). In 
a system in which it is overexpressed, LGP2 might therefore act as a 
potent negative regulator because sequestration of these ligands through 
competitive binding could prevent the activation of RIG-I and/or MDA5.  
Satoh et al. (37) demonstrated that ATPase activity is essential, using an 
LGP2 mutant that had lost its ATP-catalytic activity; expressing this 
mutant in LGP2-deficient cells failed to restore IFN production. Other in 
vitro analyses indicated, however, that ATPase is dispensable for its 
functions (39). Hence, the precise role of LGP2 is still unclear, with 
different functions being variously affected by various physiological 
conditions such as ATPase activities, RNA binding, subcellular 
localization, expression levels and involvement of unknown third-party 
components. 
In a recent report, the complement component C1qA was found to be 
essential in RIG-I-mediated IFN-β gene activation via TBK1 (40). 
Overexpression of C1qA enhanced RIG-I and MAVS-mediated IFN-β 
gene activation and, hence, efficiently suppressed viral replication in 
human 293T cells. C1qA was initially reported to be mainly produced by 
macrophages or related cell lines such as THP1; concomitantly, proteomic 
analyses from the above report (40) also indicate the strong association 
between C1qA and MAVS in the THP1 lineage. Further examination on 
the role of C1qA in RIG-I-mediated signalling in macrophages could be 
potentially interesting. In addition, FAK (focal adhesion kinase), a large 
protein complex that bridges the cytoplasm to the extracellular matrix 
through the cytoskeleton, was also shown to be essential for RIG-I-
mediated signalling through interactions with MAVS (41).  
 
Apart from these proteins, other major regulatory molecules of RLRs can 
be classified within the mitochondrial and ubiquitination machinery. In the 
following sections, we will discuss recent progress regarding how these 






Mitochondrial dynamics in RLRs antiviral signalling 
In 2005, MAVS (also known as IPS-1 [IFN-β promoter stimulator-1], 
Cardif [CARD adapter inducing IFN- β ] and VISA [virus-induced 
signalling adaptor]), the central adaptor for RLR-mediated signalling, was 
identified by four independent laboratories (42-45). This protein contains a 
CARD domain (amino acids 10–77), which is essential for signal 
transduction through homotypic interaction with CARD of RIG-I and 
MDA5; a proline-rich region (amino acids 107–173); and a 
transmembrane domain (amino acids 514–535), which is essential for 
anchoring this protein on the outer membrane of mitochondria for antiviral 
signal transduction. The discovery of this novel RLR adaptor led to an 
avalanche of analyses focusing on mitochondrial proteins. Indeed, 
subsequent articles have further enlightened our understanding of how 
mitochondria play an essential role as a central signalosome downstream 
of RLR-dependent IFN gene activation. 
 
To date, numerous mitochondrial proteins have been suggested to have a 
positive or negative regulatory role in MAVS-mediated RLR signalling. 
The first example is TOM70, a mitochondrial import receptor encoded by 
the TOMM70A gene. As reported by Liu et al. (46), TOM70, an outer 
mitochondrial membrane protein, positively regulates RLR-mediated 
signalling by recruiting TBK1 and IRF3 to MAVS, resulting in the 
formation of a supramolecular complex for signal transduction. Ectopic 
expression of TOM70 successfully enhanced IFN production and 
effectively suppressed viral replication. These analyses were further 
verified through endogenous depletion of TOM70, which abrogated IFN 
production in response to SeV infection. 
 
Although Liu and colleagues (46) succeeded in demonstrating the 
mechanistic link of MAVS–TBK1–IRF3 complex being dependent on 
cytosolic chaperone Hsp90, the hierarchical role of TOM70 in the 
proposed pathway remains unclear. In a recent report, Kasama et al. (47) 
demonstrated that exogenous expression of TOM70 failed to rescue RLR-
mediated IFN-signalling in hepatocytes after HCV infection. It was known 
that HCV could impair RLR-mediated signalling through the cleavage of 
MAVS by its NS3/4A protease (43). In the report by Kasama et al. (47), 
abrogation of the IFN-β response because of cleavage of MAVS by 
NS3/4A in the TOM70-overexpression system was still observed, 
suggesting that TOM70 works downstream of MAVS. 
 
Despite the proteomics analyses performed by Liu and colleagues (46), 
who demonstrated a strong physical association between TOM70 and 
MAVS, the mechanistic aspects of how TOM70 communicates with 
MAVS still remain unclear. Addressing these could further strengthen our 
understanding on the role of TOM70 as well as other mitochondrial 
adaptor proteins in RLR-mediated innate immunity. The mitochondrial 
network is highly dynamic even when the cell is in a quiescent state. Both 
fusion and fission processes occur regularly to maintain healthy 
mitochondrial morphology for optimum cellular metabolism. Mitofusin 
proteins are known to be essential regulators in these events. Recently, 
several reports concomitantly demonstrated that mitofusin proteins play a 
vital role in RLR-mediated signalling. Mitofusin 1 (Mfn1) regulates fusion 
events by tethering neighbouring mitochondria and was shown to be a 
positive regulator in RIG-I signalling (48,49). The study by Onoguchi et al. 
(48) undertook two approaches to verify the involvement of Mfn1: 1) The 
effect of ectopic expression; and 2) loss-of-function analyses. 
Overexpression of Mfn1 enhanced IFN-β gene activation in response to 
both NDV infection and stimulation with RNAs containing 5’-
triphosphates; moreover, both using mouse embryonic fibroblasts deficient 
in Mfn1 and endogenous depletion of Mfn1 using siRNAs severely 
impaired IFN-β gene activation. 
 
Mutagenesis analysis further indicated that GTPase domain of Mfn1 is 
essential to facilitate efficient signal transduction, suggesting that 
mitochondrial dynamics mediated by Mfn1 could be the key in modulating 
the MAVS-containing central signalosome. Indeed, distinct MAVS 
aggregation was observed using FLAG-tagging (in which an octapeptide 
tag is added using recombinant DNA technology) of cells that stably 
express MAVS; endogenous depletion of Mfn1 blocked this aggregation. 
On the basis of these results, Onoguchi et al. (48) proposed a model in 
which MAVS aggregation is essential for downstream antiviral signal 
transduction and this aggregation is mediated by Mfn1 through 
mitochondrial fusion processes. These findings were subsequently 
partially verified by Castanier et al. (49). These authors demonstrated that 
siRNA knockdown of both Mfn1 and OPA1 (optic atrophy 1) perturbed 
normal mitochondrial morphology and, hence, abrogated NF-κB and 
IRF3-dependent antiviral responses. 
 
How MAVS is aggregated upon virus infection is a particularly interesting 
area of research. In conjunction with the finding that MAVS are present on 
peroxisomes (50), reallocation of MAVS from peroxisomes to 
mitochondria might not be improbable; since both are metabolically linked 
organelles and evidence about dual redistribution of proteins under 
constitutive dynamics and interactions between both organelles is well 
established (51). In a recent report, a distinct organelle compartment called 
MAM (mitochondria-associated membrane), which connects the ER to 
mitochondria and tethering with peroxisomes, was shown to be essential 
for RIG-I functions (52), providing us some insights that the close inter-
relationship among these membranous organelles regulates RLRs in an 
orchestrated way, which includes cross-talk, and a mitochondria-
peroxisomes-ER vesicular trafficking pathway.   
 
Overproduction of inflammatory cytokines might trigger severe systemic 
diseases that might cause a high mortality and morbidity rate for the host; 
therefore stringent control exerted over various stages throughout the 
entire line of cytokine production is indispensable. In the past few decades, 
numerous negative regulators that reside on mitochondria and that 
specifically target MAVS-containing signalosomes were identified. Mfn2, 
the homologous protein of Mfn1, was found to inhibit RLR-mediated 
signalling (53). In this report, the authors demonstrated that Mfn2 
sequestered MAVS, resulting in a stable complex with a higher molecular 
weight when cells were in a quiescent state. Depletion of Mfn2 further 
enhanced RLR-mediated antiviral responses and effectively suppressed 
viral replication. 
 
There are, however, several contradictions within the reports about 
mitochondria dynamism; we do not know what exactly causes these 
discrepancies. Admittedly, the proposed model was almost entirely based 
on in vitro immunostaining experiments combined with fundamental 
lossof-function analyses, so we have no idea on what exactly happens to 
MAVS under physiological stimulus in vivo. A report published in 2011 
by Chen and et al. (54) once again drew considerable attention on MAVS 
aggregation. The authors employed elegant in vitro biochemical 
experiments and, remarkably, demonstrated that endogenous MAVS 
assembles into prion-like aggregates for efficient signal transduction, and 
these aggregates were dependent on linkage to the K63 (Lys63) residue of 
ubiquitin chains. The authors did not, however, further address whether 
prion protein (PrP)-like aggregates of MAVS are dependent on 
mitochondria dynamism, leaving the proposed model unsupported by a 
strong biochemical experimental system. 
 
There are several other RLR-related negative regulators that localize on 
mitochondria. Polo-like kinase1 prevents the interaction between MAVS 
and TRAF proteins (55). Poly(rC)-binding protein 2 inhibits RLR-
dependent signalling through proteasomal degradation of MAVS (56).  
NLRX1 prevents CARD–CARD homotypic interactions between RLRs 
and MAVS (57). The receptor for the globular head domain of 
complement component C1q (gC1qR) has a similar function to Mfn2, 
sequestering MAVS and inhibiting its signalling (58). In addition to all 
these regulators, the modulation RLR signalling was also performed, in 
part, through the ubiquitination system, as we will describe in the 









         
 
 
Essential role of ubiquitination in RLRs-mediated signalling 
Ubiquitination mediates an indispensable role in RLR-mediated signalling. 
Upon viral infection, central core components in RLR-mediated signalling, 
including RIG-I, and their binding partners will undergo robust 
ubiquitination. Activation, conjugation and ligation of ubiquitin are 
mediated, respectively, through various E1-, E2- and E3-family proteins. 
TRIM25 is a member of the tripartite motif family, members of which 
have kinds of domain: a RING finger region; one or two B-box zinc-finger 
domains; and a coiled-coil domain. TRIM25 also contains a SPRY domain 
with E3-ligase function that was first identified to be essential for RIG-I 
ubiquitination (59). Gack et al. (60) demonstrated that lysine at position 
172 of the N-terminal CARD of RIG-I is the main target for TRIM25. 
Inhibition of RIG-I signalling through TRIM25 sequestration by influenza 
NS1 further highlighted the importance of TRIM25 in this signalling.  
 
Further screening analysis revealed that Riplet, also known as RNF135 or 
REUL (RIG-I E3 ubiquitin ligase), is another RIG-I-binding partner, 
which positively regulates RIG-I signalling through K63-linked 
polyubiquitination (61-63). Loss-of-function analyses using Riplet-
deficient fibroblast further underscored the importance of this molecule in 
antiviral signal transduction. However, there were several discrepancies 
regarding the ubiquitination site of this molecule (63), further clarification 
is required. Other E3-family members, including cIAP1, cIAP2 and 
TRAF-family members such as TRAF3, TRAF2, TRAF5 and TRAF6, 
were demonstrated to be essential in controlling the downstream signalling 
pathways (31, 64-66). Both cIAP1 and cIAP2 were shown to regulate 
RIG-I through K63-linked polyubiquitination of RIP1. The TRAF-family 
E3 ligases mainly possess MAVS-binding motifs, interacting with MAVS 
upon viral infection and subsequently facilitating downstream IRF3 and/or 
NF-κB activation predominantly through K63-linked polyubiquitination. 
 
RLR-mediated signalling is stringently controlled at different stages 
through deubiquitination processes. CYLD is one of the deubiquitinases 
that interact with the CARD domain of RIG-I to remove the K63-linked 
ubiquitin chain, shutting down its signal (67). A recent report by Jung et al. 
 
(68) demonstrated that another complex, called LUBAC, negatively 
regulates RIG-I-mediated antiviral function by targeting TRIM25. LUBEC 
contains two E3-ligases— HOIL-1L (heme-oxidised IRP2 [iron regulatory 
protein 2] ubiquitin ligase 1) and HOIP. In this report, the authors 
demonstrated that LUBAC promotes K48-linked polyubiquitination of 
TRIM25, leading to proteasomal degradation. Of note, LUBAC, 
particularly its HOIL-1L E3, can act independently from HOIP to compete 
with TRIM25 for interaction with RIG-I. These suggested that there are 
two separate, independent mechanisms exerted by LUBAC to negatively 
regulate RIG-I signal transduction. How these two distinct inhibition 
pathways works might need further clarification.  
 
Deubiquitinating enzyme A (DUBA) [also known as ovarian tumour 
domain (OTUD5)], negatively regulates RIG-I signalling by interfering 
with the function of TRAF3, especially positive regulation with TBK1. 
TRAF3 is also targeted by Triad3A, which is an E3 protein that mainly 
catalyzes K48-linked polyubiquitin chains for degradation (69). Two 
negative deubiquitinating regulators — AIP4 (atrophin-1-interacting 
protein 4) and RNF5 (56,70) —are reported to promote the proteasomal 
degradation of MAVS and STING, respectively.  
 
Newly emerging RNA helicases in innate immune system  
 
Recently, several newly emerging RNA helicases were substantially 
reported to be either sensors of non-self RNA or regulators of known 
PRRs such as RIG-I. In 2010, Oshiumi et al. (71) demonstrated that the 
helicase DDX3 regulates RIG-I signalling through MAVS. A year later, 
the same group reported that the helicase DDX60 is vital to promote RIG-I 
activities (72). Liu and colleagues (73,74) further showed that the complex 
of helicases DDX1–DDX21–DHX36 and the helicase DHX9 sense 
dsRNA in mDCs, whereas the helicase DDX41 is essential for sensing 
cytoplasmic DNA (75). DDX1–DDX21–DHX36 could only function as a 
complex whereas DHX9 could work independently for this sensing 
process. Liu and colleagues (76) also demonstrated that the helicases 
DHX9 and DHX36 are essential for sensing DNA in pDCs and 
transducing downstream signals via MyD88, the downstream adaptor for 
TLRs, suggesting that there is a cross-talk between these two endosomal 
and cytoplasmic PRRs. Previous reports have, moreover, clearly shown 
that TLR9-independent but MyD88-dependent DNA sensors might exist in 
pDCs (77,78); hence, these two helicases could be the missing parts of the 
puzzle.  
 
Taken together, all these reports also concomitantly proposed the notion 
that the existence of multilayer defensive lines against viruses could 
function in cell-type-specific, (Figure 4) and/or a time-dependent manners. 
Continuing effort is, however, required to delineate the underlying 
mechanisms such as the potential cross-talk among PRRs and their 
putative downstream adaptors. Since pDCs are extremely efficient in 
detecting viral infections for the initiation of both innate and adaptive 
immune responses, multiple sensors might not be improbable and at least 
some redundancy seems likely to occur in vivo. In keeping with this notion, 
RNA helicases are well known for their association with a diverse range of 
cellular activities, especially in RNA metabolism where they affect factors 
such as RNA stability, splicing, export and maintenance of secondary 
structure (79). Most conclusions from these reports are mainly derived 
from observations obtained after deleting the endogenous gene of interest; 
admittedly, the observed impairment in cytokine production might 
therefore be due to an unknown partial defect in an RNA metabolic 
pathway, rather than elimination of a genuine viral sensor. In-depth and 
























Conclusion and Future Perspective 
 
Since the discovery of RIG-I as a novel cytoplasmic viral sensor, various 
efforts have been made to further decipher the antiviral functions of RLRs, 
especially RIG-I. There are still, however, many fundamental questions 
that remain poorly understood; for example, little is still known about 
either MDA5 or LGP2. As noted above, the functional role of LGP2 as a 
regulatory molecule for RIG-I and MDA5 is still controversial, so more 
studies are needed to precisely assess its contribution. In conclusion, RLRs 
possess an indispensable role in mounting defenses against non-self RNA, 
greater understanding of the underlying molecular mechanisms of RLR 
activation and regulation could open new doors for the design of 
therapeutic strategies against viral infection.  
 
 
On the other hand, previous efforts to generate RIG-I-knockout mice 
posed daunting challenges because RIG-I deficiency causes embryonic 
lethality in certain genetic backgrounds, suggesting that there are diverse 
cellular functions of RIG-I distinct from antiviral defense, probably in the 
developmental processes. Indeed, in a recent report, Liu et al. (80) 
revealed a new role for RIG-I in the aging process, and this phenotype was 
mediated through a well-known anti-aging factor known as Klotho (81). 
Liu et al. (80) showed that Klotho functions as an anti-aging factor by 
suppressing RIG-I-mediated inflammation. This report has opened a new 
direction of research on RIG-I, other than IFN-mediated antiviral response, 
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FIGURE 2.  Schematic models of the structure of RIG-I before and after ligands detection 
The CTD is essential for recognising the 5’-triphosphate of viral PAMPs. (A) Because the CTD is also known to possess an RD, 
in the initially widely accepted model the CTD was proposed to maintain RIG-I in a quiescent state. Upon viral detection there 
would be a conformational change that exposes the CARD domains and allows signalling. (B) Following recent structural 
analyses, a new model was proposed. RIG-I remains in an autorepressed state with its two tandem CARD repeats binding to the 
helicase Hel2i, preventing the helicase region from binding viral dsRNA and other interacting proteins; whereas the CTD is 
flexibly exposed for detection of dsRNA. Upon binding 5’-triphosphate, the CTD is flexibly repositioned to allow dsRNA 
binding at the helicase region. Coupled with ATP binding, this cooperative binding induces the formation of a high-affinity and 
stable helicase–dsRNA closed-clamping structure, sterically propelling the CARD domains outwards and exposing them for 
interaction with MAVS. 
FIGURE 1  Schematic structural representation of RIG-I-like family members and their signaling adaptor MAVS.  
The RLR family consists of RIG-I, MDA5 and LGP2. All RLRs contain a DExD/H-box helicase domain containing ATPase 
activity; a C-terminal domain (CTD) for functional repression or autoregulation, and CARD domains at the N-terminus of both 
RIG-I and MDA5 but not LGP2. These RLRs signal through a common adaptor MAVS/IPS1, which contains a transmembrane 
domain (TMD) at the C-terminal region, a proline-rich region (PRR) and a homologous CARD at the N-terminus. 
FIGURE 3.  Comparisons of majors cellular PRRS (RLRs, TLRs) for first line antiviral defense. 
(A) The cytosolic viral sensors RIG-I and MDA5 detect invaded viral dsRNA. Upon binding, both RIG-I and MDA5 undergo 
conformational change and (B) interact with MAVS localized on the mitochondrial membrane, inducing the recruitment of 
various regulatory components and activating both NF-κB and IRF3 for production of type I interferons. Riplet and TRIM25 
mediate RIG-I ubiquitination. STING/MITA/ERIS/MYPS, a positive regulator of RLR signaling is reported to localize on either 
ER or outer-membrane of mitochondria. Since ER is tightly juxtaposed to mitochondria, the term for ‘MAM’ is proposed for 
this area. (C) Cytosolic RNA polymerase III was identified as a DNA sensor, generating RNA templates from the viral DNA that 
act as ligands for RLRs. (D) TLRs are the major transmembrane PRRs. Upon PAMP detection, TLR2 and TLR4 will recruit the 
downstream adaptor molecule TIRAP and subsequently MyD88, whereas (E) endosome-localized TLR3, TLR7 and TLR9 will 
be re-compartmentalized through an ER protein, UNC93B. TLR2, 7 and 9 activate the transcription of inflammatory cytokines 
and IFNs through MyD88-dependent pathways, whereas TLR4 and 3 activate through a TRIF/TICAM-dependent pathway. 
 
FIGURE 4.  Antiviral recognition of viruses by PRRs in dendritic-cell populations.  
(A) Endosome-localized TLR3 and (B) the cytosolic viral sensors of the RLR family are well-known sensors for viral dsRNA in 
mDCs. Upon detection of PAMPs, RLRs will interact and transmit downstream signals through the MAVS signalosome, 
whereas TLR3 recruits TRIF/TICAM for both IRF3 and NF-κB activation. (C) The RNA helicase DHX9 and (D) the complex 
of three helicases DDX1–DDX21–DHX36 were identified as vital PRRs for recognition of viral dsRNA in mDCs. DHX9 works 
independently and pairs with MAVS for signal transduction upon detection. The DDX1–DDX21–DHX36 complex activates 
production of cytokines and pro-inflammatory cytokines through TRIF/TICAM — a common downstream adaptor with TLR3. 
(E) DDX41 was shown to have an essential role in detecting viral DNA in cDCs. This molecule signals through STING and 
activates IRF3 via TBK1. (F) In pDCs, endosome-localized TLR7 and TLR9 are well known for detection of viral RNA and 
DNA, respectively. (G) Two cytosolic DNA sensors in pDCs have been identified: DHX36 and DHX9. DHX36 detects cytidine-
phosphate-guanosine-A (CpG-A) and recruits MyD88 as the downstream adaptor, transmitting through IRF7 activation; DHX9 
also recruits MyD88 upon recognition with cytidine-phosphate-guanosine-B and activates cytokine production through NF-κB. 
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a) Triacyl lipopeptides   
b) Soluble lipoproteins 
a) Mycobacteria 
b) Bacteria, eg. Neisseria meningitides 
c) Synthetic compound, eg. Pam3CSK4 
3, 83, 86 
TLR2 
a) Peptidoglycan 
b) lipoteichoic acid 
c) Lipoprotein 
d) lipoarabinomannan  
e) zymosan 
a) Gram (+) and (-) bacteria 
b) Mycobacteria 
c) Yeast cell wall 




b) synthetic polyI:C (<8000 bp) 
dsRNA viruses 
3, 83, 85, 
86 
TLR4 LPS, flavolipin  
a) Gram-negative bacteria, eg, 
Flavobacterium meningosepticum 
3, 83, 86 
TLR5 Flagellin  
Bacteria with flagellum, eg. Salmonella 
typhimurium 
3, 83, 86 
TLR6/2  Diacyl lipopeptides  
a) Mycoplasma fermentans  
b) yeast zymosan from S. cerevisiae, 
c) lipoteichoic acid from group B 
Streptococci and Staphylococci 




b) Nucleoside analogs  
a) RNA viruses 
b) Vaccine adjuvant-R848 
c) Synthetic ss-poly U rich RNAs 
3, 83, 85, 
86 
TLR9 
a) specific unmethylated CpG 
oligonucleotides (ODN) motif;  
b) Hemozoin in parasite  
c) DNA 
a)  Plasmodium 
b) DNA virus eg. HSV 
c) CpG motif in bacteria and protozoa 




a) Short double stranded synthetic 
RNAs (<1000 bp);  
b) PolyU/UC rich RNA;  
c) 5’-triphosphate RNAs;  
d) RNaseL RNA fragments  
e) RNAs with panhandle structure   
a) ssRNA viruses, eg. HCV poly U/UC 
rich segment; IAV strain A and B; 
VSV, SeV, NDV, RSV, MV, NiV; 
b) dsRNA virus, eg. reovirus.   
11, 13, 16, 
17, 19 
MDA5 
a) Long synthetic polyI:C (>1000 bp) 
with mono- and/or diphosphate 
ends;  
b) RNaseL-cleaved self RNAs with 
monophosphate ends;  
c) High-order of RNA web 
a) Picornaviruses, eg.  EMCV, TMEV, 
poliovirus, mengo virus 
b) DNA virus, eg. Vaccina virus. 
c) dsRNA virus, eg. reovirus.   
11, 16, 19, 
82  
Table 1     PAMPs for RLRs and TLRs  
